Moving precision forward: extending next generation sequencing to operable disease in less common breast cancer subtypes

Ann Oncol. 2024 Jan;35(1):7-9. doi: 10.1016/j.annonc.2023.10.127. Epub 2023 Oct 21.

Authors

A Thomas¹, R Shatsky², K Kalinsky³

Affiliations

¹ Section on Hematology and Oncology, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem. Electronic address: althomas@wakehealth.edu.
² Department of Medicine, University of California, San Diego. Electronic address: https://twitter.com/dr_rshatsky.
³ Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, USA. Electronic address: https://twitter.com/kalinskykevin.

PMID: 37871698
DOI: 10.1016/j.annonc.2023.10.127

No abstract available

Publication types

Editorial

MeSH terms

Breast Neoplasms* / genetics
Breast Neoplasms* / surgery
Female
High-Throughput Nucleotide Sequencing
Humans
Mutation
Receptor, ErbB-2

Substances

Receptor, ErbB-2